The GOG 3026 trial demonstrated that ribociclib and letrozole combination therapy achieved a 31% response rate and 84% ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...
The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Corcept Therapeutics, sponsor of the ROSELLA trial, is currently evaluating relacorilant in other solid tumors, including platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, ...
This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...
Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results